SMMT
Summit Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.62
−3.57%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -48.2%
- EBIT
- -48.4%
- EPS
- -42.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -14.7%
- EPS
- -12.8%
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026